Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
BMBioMarin Pharmaceutical Inc. logo

BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ Global Select · Currency in USD
$55.95 ▼ -0.68 (-1.20%)
At close: Oct 23, 4:00 PM ET. Market closed.
$55.95 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$56.63
Open
$56.68
Day's Range
$55.24 – $56.81
52 Week Range
$49.26 – $70.98
Volume
1,682,821
Avg. Volume
2,101,173
Market Cap
$10.83B
Beta (5Y Monthly)
0.22
PE Ratio (TTM)
147.24
EPS (TTM)
$0.38
Earnings Date
Oct 26, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$90.94

Profile: BioMarin Pharmaceutical Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3,221
CEO
Alexander Hardy

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI.

Earnings

Next report: Mon, Oct 26, 2026
EPS estimate -$0.09 · Revenue est. $1.02B
DateEst.Actual
Aug 6, 2026$0.95$1.20Beat
May 4, 2026$0.78$0.76Miss
Feb 23, 2026$0.17-$0.24Miss
Oct 27, 2025-$0.15-$0.16Miss
Aug 4, 2025$0.86$1.23Beat
May 1, 2025$0.71$0.97Beat

Analyst view

Consensus price target
$90.94 ▲ +62.5%
Range $59.00 – $122.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on BMRN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.